Telomir Pharmaceuticals, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $85.3M
- Price
- $1.24
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.81%
- Volume
- 34.9K
Quote data as of 5:26 AM ET
About
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Quick stats
Shares outstanding68.8M
Computed float53.8M
Float sourceUnknown
Cash runway (months)9.5
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001971532
Websitehttps://telomirpharma.com
AI Summary
AI-generated2mo agostandardbullishclinical trialTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in Advances in Redox Research.
The study demonstrated dose-dependent survival improvement and reduced hepatic copper burden in a zebrafish model of Wilson's disease.
The findings support the drug's mechanism of modulating intracellular copper and oxidative stress, reinforcing the scientific basis for its lead program in Triple-Negative Breast Cancer, which received FDA IND clearance in April 2026.